e-learning
resources
Munich 2006
Sunday 03.09.2006
Spirometric assessment of lung pathophysiology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bronchodilator reversibility testing in COPD: which parameter?
N. Bautin, C. Chenivesse, T. Perez, R. Matran (Lille, France)
Source:
Annual Congress 2006 - Spirometric assessment of lung pathophysiology
Session:
Spirometric assessment of lung pathophysiology
Session type:
Thematic Poster Session
Number:
1212
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Bautin, C. Chenivesse, T. Perez, R. Matran (Lille, France). Bronchodilator reversibility testing in COPD: which parameter?. Eur Respir J 2006; 28: Suppl. 50, 1212
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The physiology of breathlessness
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Bronchodilator reversibility - differences between asthma and COPD
Source: International Congress 2019 – Respiratory function assessment in disease
Year: 2019
Ventilation heterogeneity reversibility: asthma, COPD or ACOS?
Source: International Congress 2017 – Novel imaging findings characterising various lung diseases and their prognoses
Year: 2017
Assessment of lung volumes and capacities in bronchodilator reversibility changes of hyperinflation of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
Bronchodilator reversibility (BDR) - should we measure it in adults with symptoms but without obstructed spirometry?
Source: Virtual Congress 2021 – Primary care diagnosis and multimorbidities
Year: 2021
Body-plethysmographic measurements of bronchodilator response in stable COPD
Source: International Congress 2014 – Airways: reversibility and responsiveness
Year: 2014
Comparison of protective effect of bronchodilators in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Bronchodilator responsiveness in patients with COPD
Source: Eur Respir J 2008; 31: 742-750
Year: 2008
Bronchodilator reversibility in asthma and COPD: findings from three large population studies
Source: Eur Respir J, 54 (3) 1900561; 10.1183/13993003.00561-2019
Year: 2019
Bronchodilation test estimation using spirometry and electrical impedance analysis in bronchial asthma and COPD patients
Source: International Congress 2015 – Lung function: new findings and approaches
Year: 2015
Spirometry parameters and adherence to COPD treatment: is there association?
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020
Usefulness of post bronchodilator FVC in the evaluation and spirometric evolution of COPD patients
Source: Annual Congress 2013 –Monitoring lung function in airway diseases
Year: 2013
Reversibility at pulmonary function tests: can it have implications in patients with COPD?
Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD
Year: 2021
Bronchodilator response of advanced lung function parameters depending on COPD severity
Source: International Congress 2016 – Functional assessment of the airways
Year: 2016
Are bronchodilator drugs really useful in COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 94s
Year: 2001
Airway calibre variability by forced oscillation technique: a sensitive indicator of bronchodilator effect in asthmatic children
Source: Annual Congress 2005 - Monitoring paediatric asthma
Year: 2005
Optimising bronchodilator therapy in COPD: Who, why and when?
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019
Does positive bronchodilator reversibility testing predict positive bronchoprovocative methacholine challenge testing in suspected asthma patients
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013
Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI
Source: Virtual Congress 2020 – New imaging techniques applied to old problems
Year: 2020
REVERDIL study: validity of salbutamol in determining COPD reversibility prior to formoterol treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept